Secondary preventive program atherosclerosis in a university hospital. Results and predictors of clinical course;Programa de Prevención secundaria de la arteriosclerosis de un hospital universitario. Resultados y factores predictivos del curso clínico

Medicina Clinica

Volumn 120, Issue 20, 2003, Pages 768-772

  Pintó, Xavier ^a   Meco, José F ^a   Corbella, Emili ^a   Figueras, Rosaura ^a   Pallarés, Carlos ^a   Esplugas, Enric ^a   Castiñesras, María J ^a   Marrugat, Jaume ^b   Pujol, Ramon ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Coronary disease; Lipoproteins; Preventive programs; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTERVIEW; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CODING; PREDICTION; SECONDARY PREVENTION; SPAIN; SURVIVAL TIME; TELEPHONE; UNIVERSITY HOSPITAL;

EID: 0038639834     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048328     Document Type: Article

References (30)

1. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700-7.
2. Egger M, Smith GD, Pfluger D, Altpeter E, Elwood PC, Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. Atherosclerosis 1999; 143:275-84.
3. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Op Lipidol 1996; 7:209-16.
4. Smith SC Jr. Lessons from cholesterol-lowering trials. Am J Med 1998;104(Suppl 6A):28-32.
5. Goldman L, Garber AM, Grover SA, Hlatky MA. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27:1020-30.
6. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
7. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Int Med 2000;160:459-67.
8. Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol 1998;81:1416-20.
9. Brotons C, Server M, Pintó X, Roura P, Martín-Zurro A. Impacto de los consensos para el control de la colesterolemia y la hipertensión en España. Med Clin (Barc) 1997;108:9-15.
10. Superko HR, Desmond DA, DeSantos VV, Vranizan KM, Farquhar JW. Blood cholesterol treatment attitudes of community physicians: a major problem. Am Heart J 1998;116:849-55.
11. Meco JF, Pintó X, Escribà JM, Vela M, Jara F, Pallarés C, et al. Cardiovascular risk factors associated with clinically isolated and diffuse atherosclerosis in Spanish patients with coronary artery disease. Eur J Clin Invest 1998;28:643-50.
12. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Cardiovascular Diseases. Nutr Metab Cardiovasc Dis 1992;2:113-56.
13. Ballantyne CM. Current thinking in lipid lowering. Am J Med 1998;104(Suppl 6A):33-41.
14. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69.
15. Grupo de Investigación del estudio PREMISE. Prevención secundaria del infarto de miocardio y calidad de vida relacionada con la salud. Med Clin (Barc) 2002;119:9-12.
16. Grupo de Investigación del estudio ELIPSE (el Estudio de Lipidos en Prevención Secundaria de cardiopatía isquémica). Prevención secundaria de la cardiopatía isquémica en la provincia de Ciudad Real. Efectividad de la terapéutica hipolipemiante en atención primaria. Med Clin (Barc) 2000;115:321-5.
17. De Velasco JA, Cosín J, López-Sendón JL, De Teresa E, De Oya M, Carrasco JL, et al. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol 1997;50:406-15.
18. Ornish D, for the Multicenter Lifestyle Demonstration Project Research Group. Avoiding revascularization with lifestyle changes: the Multicenter Lifestyle Demonstration Project. Am J Cardiol 1998;82:72T-6T.
19. Pintó X. Genes, hypercholesterolemia and carotid atherosclerosis. Eur J Clin Invest 1998;28: 980-2.
20. Meyers DG. Relative survival benefits of risk factor modifications. Am J Cardiol 1996;77:298-9.
21. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barret-Connor E. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2468-82.
22. Marrugat J, Sanz G, Masia R, Valle V, Molina L, Cardona M, et al. Six-month outcome in patients with myocardial infarction initially admitted to tertiary and nontertiary hospitals. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol 1997;30:1187-92.
23. Álvarez-Sala Walther LA, Millán Núñez-Cortés J. Evidencias de la eficacia del tratamiento hipocolesterolemiante en la prevencón primaria y secundaria de la cardiopatía isquémica. Med Clin (Barc) 2000;114(Supl 2):1-10.
24. Thompson GR. The proving of the lipid hypothesis. Curr Opinion Lipidol 1999;10:201-5.
25. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation 1992;86 (Suppl 3):86-94.
26. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease. Can J Cardiol 1988;4 (Suppl):5-10.
27. Castelli WP. The new pathophysiology of coronary artery disease. Am J Cardiol 1998;82:60T-5T.
28. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Circulation 1997;17: 1114-20.
29. Bloomfield Rubins H, Robins SJ, Collins D, Collins D, Fye CL, Anderson JW, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
30. Grundy SM. Consensus statement. Role of therapy with statins in patients with hypertriglyceridemia. Am J Cardiol 1998;81(Suppl 4A):1-6.